# JAK2 V617F Genetic Variant Enrichment - Complete Report

**Date:** 2026-01-29
**Score Item ID:** 99985045-0d9c-4454-bd86-0518136f4675
**Item Name:** JAK2 - pesquisa da variante genética c.1849G>T (p.V617F)

---

## Execution Summary

### Status: COMPLETE ✓

The JAK2 V617F score item has been successfully enriched with comprehensive clinical content in Portuguese (PT-BR) and linked to 4 peer-reviewed scientific articles from high-impact journals (2023-2024).

---

## Content Verification

### Character Counts

| Field | Character Count | Target Range | Status |
|-------|----------------|--------------|--------|
| `clinical_relevance` | 1,536 | 1,500-2,000 | ✓ PASS |
| `patient_explanation` | 1,383 | 1,000-1,500 | ✓ PASS |
| `conduct` | 1,904 | 1,500-2,500 | ✓ PASS |

All fields meet the specified character count requirements.

### Last Review Date

- **Updated:** 2026-01-29

---

## Clinical Content Summary

### Clinical Relevance (1,536 characters)

Comprehensive overview covering:
- **Prevalence:** 97% in polycythemia vera (PV), 55-60% in essential thrombocythemia (ET), 50-60% in primary myelofibrosis
- **Molecular Mechanism:** Gain-of-function mutation causing constitutive JAK-STAT pathway activation
- **Diagnostic Criteria:** Major criterion per WHO 5th edition (2022) and ICC 2022 classification
- **Prognostic Significance:** Variant allele frequency (VAF) correlates with thrombotic risk, myelofibrosis transformation (OR 2.8), acute leukemia (OR 3.2)
- **Clinical Thresholds:** VAF ≥30% in ET associated with PV-like phenotype, higher thrombosis rate (2.1% vs 1.4% patient/year)
- **Detection Methods:** Real-time PCR or next-generation sequencing (NGS) with 1-3% sensitivity
- **Therapeutic Monitoring:** VAF tracking during JAK2 inhibitor therapy (ruxolitinib, fedratinib) or pegylated interferon

### Patient Explanation (1,383 characters)

Patient-friendly language explaining:
- What the JAK2 V617F mutation is and how it causes uncontrolled blood cell production
- Associated diseases: polycythemia vera, essential thrombocythemia, myelofibrosis
- Clinical implications of positive result
- Meaning of "allele burden" and prognostic value
- Higher allele burden (>50-60%) indicates more advanced disease and increased risk
- Simple blood test procedure
- Impact on treatment decisions including JAK2 inhibitors and cardiovascular risk stratification

### Conduct (1,904 characters)

Detailed clinical management guidelines:

**Indications:**
- Erythrocytosis (Hgb >16.5 g/dL men, >16 g/dL women)
- Persistent thrombocytosis (platelets >450,000/mm³)
- Unexplained splenomegaly
- Aquagenic pruritus
- Splanchnic thrombosis (Budd-Chiari, portal/mesenteric thrombosis)

**Interpretation:**
- POSITIVE: Confirms JAK2-mutated MPN (WHO 2022 major criterion)
- VAF <25%: suggests ET
- VAF 25-50%: ET or PV
- VAF >50-75%: PV with higher evolutionary risk
- NEGATIVE in PV suspicion: test JAK2 exon 12 mutations (2-3% of PV cases)
- NEGATIVE in ET/MF suspicion: test CALR (20-25%) and MPL (3-5%) mutations

**Risk Stratification:**
- PV: Low risk (age <60 + no prior thrombosis) vs High risk (age ≥60 OR thrombosis history)
- ET JAK2-positive: consider age >60, VAF ≥30%, Hgb >15 g/dL, leukocytosis as additional thrombotic risk factors

**Monitoring:**
- Repeat VAF measurement every 6 months during cytoreductive therapy or pegylated interferon
- >50% VAF reduction correlates with better clinical control and lower progression

**Therapeutic Management:**
- High risk or VAF >50%: hydroxyurea (target Hct <45%), pegylated interferon (ropeginterferon alfa-2b), or JAK2 inhibitors (ruxolitinib 10-25 mg BID in myelofibrosis or refractory PV)
- Low risk: phlebotomy (target Hct <45%) + aspirin 100 mg/day
- Consider anticoagulation for prior thrombosis
- Refer to hematologist for diagnostic confirmation, WHO classification, and individualized therapy

---

## Scientific Articles Linked

### Article 1: Zhang et al. (2024) - Cancer
**PMID:** 39277798
**Title:** New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms
**Authors:** Zhang Y, Zhao Y, Liu Y, Zhang M, Zhang J
**Journal:** Cancer
**Publication Date:** December 15, 2024
**Type:** Review

**Key Contributions:**
- Most comprehensive 2024 review on JAK2 V617F mutation
- Explores mechanisms beyond JAK-STAT pathway
- Covers regulation of cellular methylation
- Discusses DNA damage accumulation
- Addresses cardiovascular system effects
- Implications for targeted therapy with JAK inhibitors

### Article 2: Álvarez-Reguera et al. (2024) - European Journal of Internal Medicine
**PMID:** 38044168
**Title:** Features of immune mediated diseases in JAK2 (V617F)-positive myeloproliferative neoplasms and the potential therapeutic role of JAK inhibitors
**Authors:** Álvarez-Reguera C, Prieto-Peña D, Herrero-Morant A, Sánchez-Bilbao L, Batlle-López A, Fernández-Luis S, Paz-Gandiaga N, Blanco R
**Journal:** European Journal of Internal Medicine
**Publication Date:** January 1, 2024
**Type:** Research Article

**Key Contributions:**
- Pro-inflammatory phenotype of JAK2 V617F mutation
- High prevalence of rheumatic immune-mediated diseases in MPN patients
- Therapeutic potential of JAK inhibitors for concurrent autoimmune conditions

### Article 3: Tefferi & Barbui (2023) - American Journal of Hematology
**PMID:** 37357958
**Title:** Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management
**Authors:** Tefferi A, Barbui T
**Journal:** American Journal of Hematology
**Publication Date:** September 1, 2023
**Type:** Review

**Key Contributions:**
- Comprehensive 2024 update on PV diagnosis including JAK2 V617F detection
- Risk stratification based on age and thrombosis history
- Current management strategies with cytoreductive therapy
- JAK inhibitor treatment protocols
- WHO diagnostic criteria application

### Article 4: Moliterno et al. (2023) - Blood
**PMID:** 36745865
**Title:** JAK2 V617F allele burden in polycythemia vera: burden of proof
**Authors:** Moliterno AR, Kaizer H, Reeves BN
**Journal:** Blood
**Publication Date:** April 20, 2023
**Type:** Review

**Key Contributions:**
- Critical examination of JAK2 V617F variant allele frequency (VAF) as prognostic marker
- Thrombotic risk correlation with allele burden
- Disease progression to myelofibrosis
- Transformation to acute leukemia risk assessment
- Clinical utility of VAF monitoring

---

## Database Schema Compliance

### Table: `score_items`
- ✓ `id` (UUID): 99985045-0d9c-4454-bd86-0518136f4675
- ✓ `clinical_relevance` (TEXT): 1,536 characters
- ✓ `patient_explanation` (TEXT): 1,383 characters
- ✓ `conduct` (TEXT): 1,904 characters
- ✓ `last_review` (DATE): 2026-01-29

### Table: `articles`
- ✓ Column name: `pm_id` (NOT pmid)
- ✓ Column name: `publish_date` as date type (NOT year)
- ✓ NO url column used
- ✓ Article type enum values validated: 'review', 'research_article'
- ✓ All 4 articles inserted successfully

### Junction Table: `article_score_items`
- ✓ Table name: `article_score_items` (NOT score_item_articles)
- ✓ NO created_at column
- ✓ All 4 article links created successfully
- ✓ Total articles linked to this score item: 13 (includes previous MFI lecture links)

---

## SQL Execution Details

**Script Location:** `/home/user/plenya/scripts/enrich_jak2_v617f.sql`

**Execution Method:**
```bash
cat /home/user/plenya/scripts/enrich_jak2_v617f.sql | \
docker compose -f /home/user/plenya/docker-compose.yml exec -T db \
psql -U plenya_user -d plenya_db
```

**Transaction Status:** COMMITTED ✓

**Records Modified:**
- 1 score_item updated
- 4 articles inserted (with duplicate prevention)
- 4 article-score_item links created

---

## Research Focus Areas Covered

### 1. JAK2 V617F in Myeloproliferative Neoplasms
- Polycythemia vera (97% prevalence)
- Essential thrombocythemia (55-60% prevalence)
- Primary myelofibrosis (50-60% prevalence)

### 2. Allele Burden Significance
- Variant allele frequency (VAF) as prognostic marker
- Correlation with thrombotic risk
- Disease progression indicators
- Transformation risk assessment

### 3. Thrombotic Risk
- Venous thromboembolism correlation with VAF
- Arterial thrombosis risk factors
- Splanchnic vein thrombosis
- Age and leukocytosis as additional factors

### 4. WHO 2022 Diagnostic Criteria
- JAK2 V617F as major diagnostic criterion
- WHO 5th edition (2022) classification
- International Consensus Classification (ICC) 2022
- Integration with clinical and histopathological criteria

### 5. JAK2 Inhibitors
- Ruxolitinib (first-line JAK1/JAK2 inhibitor)
- Fedratinib (selective JAK2 inhibitor)
- Pacritinib (selective JAK2 inhibitor)
- Combination therapies with hypomethylating agents
- Limited impact on allele burden
- Role in autoimmune complications

### 6. Additional Mechanisms
- Non-JAK-STAT pathways
- Cellular methylation regulation
- DNA damage accumulation
- Cardiovascular effects
- Pro-inflammatory phenotype

---

## Quality Assurance

### Content Quality
- ✓ All content in Portuguese (PT-BR)
- ✓ Clinical accuracy verified against 2023-2024 literature
- ✓ Evidence-based recommendations
- ✓ Patient-friendly explanations without medical jargon
- ✓ Comprehensive clinical conduct guidelines

### Technical Quality
- ✓ Proper database schema compliance
- ✓ Correct table and column names
- ✓ Valid enum values for article_type
- ✓ Date format compliance ('YYYY-MM-DD'::date)
- ✓ Duplicate prevention logic implemented

### Article Quality
- ✓ All articles from peer-reviewed journals
- ✓ Publication years 2023-2024 (within 5-year window)
- ✓ High-impact journals (Blood, Cancer, Am J Hematol, Eur J Intern Med)
- ✓ Valid PubMed IDs verified
- ✓ Diverse article types (3 reviews, 1 research article)

---

## Files Generated

1. **SQL Script:** `/home/user/plenya/scripts/enrich_jak2_v617f.sql`
   - Comprehensive enrichment script
   - Transaction-safe (BEGIN/COMMIT)
   - Verification queries included
   - Character count validation

2. **Report:** `/home/user/plenya/JAK2-V617F-ENRICHMENT-REPORT.md`
   - Complete enrichment documentation
   - Execution summary
   - Content verification
   - Article details

---

## Conclusion

The JAK2 V617F score item enrichment has been completed successfully with:

- **Clinical Content:** High-quality Portuguese content covering all required aspects
- **Character Counts:** All within specified ranges
- **Scientific Articles:** 4 peer-reviewed articles from top-tier journals (2023-2024)
- **Database Compliance:** Full adherence to Plenya EMR schema
- **Quality Assurance:** Verified for accuracy, completeness, and technical correctness

The enriched content provides comprehensive clinical guidance for healthcare professionals regarding JAK2 V617F testing in myeloproliferative neoplasms, including diagnostic criteria, prognostic significance, risk stratification, and therapeutic management with JAK inhibitors.

---

## Sources

### Web Search Results

- [Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management](https://pubmed.ncbi.nlm.nih.gov/37357958/)
- [JAK2 V617F allele burden in polycythemia vera: burden of proof](https://ashpublications.org/blood/article/141/16/1934/494354/JAK2V617F-allele-burden-in-polycythemia-vera)
- [Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: systematic review and meta-analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC11090937/)
- [JAK2 mutations in polycythemia vera: from molecular origins to inflammatory pathways and clinical implications](https://link.springer.com/article/10.1007/s12254-024-01009-0)
- [New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms](https://pubmed.ncbi.nlm.nih.gov/39277798/)
- [Features of immune mediated diseases in JAK2 (V617F)-positive myeloproliferative neoplasms](https://pubmed.ncbi.nlm.nih.gov/38044168/)
- [JAK inhibitors for myeloproliferative neoplasms treatment](https://pmc.ncbi.nlm.nih.gov/articles/PMC11567979/)

---

**Report Generated:** 2026-01-29
**Powered by:** Claude Sonnet 4.5
**System:** Plenya EMR - Data Science & SQL Analysis
